GlaxoSmithKline Pakistan Sets Close Period Ahead of Board Meeting

Karachi: The Board of Directors of GlaxoSmithKline Pakistan Limited (GSK Pakistan Ltd) has scheduled a critical meeting on August 23, 2024, at the company’s head office in Karachi to review the financial results for the half year ended June 30, 2024. The meeting will play a pivotal role in assessing the company’s mid-year financial performance.

In preparation for this meeting, GSK Pakistan Ltd has announced a close period starting from August 16, 2024, until August 23, 2024, in compliance with clause 5.6.4 of the Rule Book of Pakistan Stock Exchange. During this period, major stakeholders such as Directors, the Chief Executive Officer, Chief Financial Officer, Company Secretary, substantial shareholders, and other executives are prohibited from buying or selling company shares. The prohibition also extends to their spouses, whether such dealings are direct or indirect.

According to information available from the Pakistan Stock Exchange (PSX), this regulatory measure ensures transparency and fairness in the handling of insider information prior to its public release. It is a standard practice meant to prevent any insider trading or conflicts of interest during times when significant financial information is being prepared and reviewed.

The company has taken thorough steps to communicate the details of the close period to all employees, reinforcing the seriousness with which it approaches regulatory compliance and corporate governance. A formal notice has also been circulated to the certificate holders of the exchange to keep them informed of the restrictions in place during this critical financial review period.

The post GlaxoSmithKline Pakistan Sets Close Period Ahead of Board Meeting appeared first on .